KR20050068196A - Pharmatheutical composition for anti-cancer and anti-cancer adjuvent - Google Patents

Abstract

The present invention relates to an anticancer and anticancer pharmaceutical composition, and more particularly, to an anticancer and anticancer pharmaceutical composition containing a conventional anticancer agent and red ginseng acidic polysaccharide (RGAP). By co-administration of anticancer agent and red ginseng acid polysaccharide, the synergistic effect of the drug can be maximized even at a small dose of the existing anticancer agent, and the anticancer activity can be maximized. It relates to an anticancer and anticancer pharmaceutical composition.

Description

Pharmaceutical composition for anti-cancer and anti-cancer support {PHARMATHEUTICAL COMPOSITION FOR ANTI-CANCER AND ANTI-CANCER ADJUVENT}

The present invention relates to an anticancer and anticancer pharmaceutical composition, and more particularly, to an anticancer and anticancer pharmaceutical composition containing a conventional anticancer agent and red ginseng acidic polysaccharide (RGAP). By co-administration of anticancer agent and red ginseng acid polysaccharide, the synergistic effect of the drug can be maximized even at a small dose of the existing anticancer agent, and the anticancer activity can be maximized. It relates to an anticancer and anticancer pharmaceutical composition.

Most anti-cancer drugs currently in use are limited in use due to severe toxicity and side effects, and the dose is increased to increase the therapeutic effect as well as anti-cancer multi-drug resistance.

In particular, the anti-cancer agent cyclophosphamide (CY) is an alkylating agent that inhibits DNA replication and RNA transcription and shows anti-cancer activity. It is a widely used anti-cancer agent for acute / chronic leukemia and other solid cancers, but it has severe immunosuppressive (immune toxicity) action. Indicates.

In addition, 5-fluorouracil (5-Fu) is a pyrimidine derivative that inhibits hexane metabolism and mainly has anticancer effects on breast cancer, colon cancer, gastric cancer, pancreatic cancer, etc., but myelosuppression, oral cavity, peptic ulcer, liver and Side effects such as kidney damage are limited (Katzung, BG Katzung's Clinical Pharmacology, 8th Edition, The Korean Medical Book, Seoul, p977-1015, 2001).

In order to alleviate the toxicity and side effects of existing anticancer agents, an example of a combination of an anticancer agent and an acidic polysaccharide fractionated from Panax ginseng CA Meyer has been reported (Kim, YS et.al., Arch. Pharm. Res. 13: 330, 1990).

However, the prior art is aimed at suppressing immunotoxicity and inhibiting cancer development of cancer cells (Sarcoma-180) transplanted mice and enhancing phagocytic activity of the intranet system by administering the anti-cancer agent cyclophosphamide and ginseng acid polysaccharide in combination. Combined administration of and ginseng acidic polysaccharides did not significantly reduce the dose of anticancer drugs needed to achieve equivalent anticancer effects, and did not fundamentally solve the toxicity and side effects of anticancer drugs.

The present inventors isolated red ginseng acidic polysaccharide (RGAP) from red ginseng in Korean Patent Application No. 2001-33115, an acidic polysaccharide having a new anticancer immunomodulatory effect different from that of white ginseng. It has been reported.

In addition, the present inventors have shown synergistic effect when the red ginseng acid polysaccharide (RGAP) is mixed with Taxol, which is clinically applied to the treatment of breast cancer and ovarian cancer, in Korean Patent Application No. 2002-53950 to increase anticancer activity. It has been disclosed that the same anticancer effect can be obtained even at a small dose of taxol.

In addition to the above-described results, the present inventors have continued the study of co-administering red ginseng acid polysaccharide (RGAP) with respect to existing anticancer agents other than taxol, and as a result, co-administration of the existing anticancer agent with red ginseng acid polysaccharide (RGAP) Because of the synergistic effect of the drug, it shows an increase in anticancer activity, and even a small dose of anticancer agent can show the same anticancer effect, and also indirect protective effect to reduce the toxicity caused by anticancer agent can be obtained. The invention has been completed.

Accordingly, the present invention provides an anticancer and anticancer pharmaceutical composition containing an anticancer agent and red ginseng acid polysaccharide.

In another aspect, the present invention is to provide a pharmaceutical composition for anticancer and anticancer aid that can maximize the anticancer activity by showing a synergistic effect of the drug even at a small dose of the anticancer agent by the combined administration of anticancer agent and red ginseng acid polysaccharide.

In addition, the present invention provides an anticancer and anticancer pharmaceutical composition that can reduce the toxicity and side effects of the anticancer agent by using a small dose of the anticancer agent.

In order to achieve the above object, the present invention provides an anticancer and anticancer pharmaceutical composition containing an anticancer agent and red ginseng acid polysaccharide (RGAP) as an active ingredient.

In particular, the present invention provides an anticancer and anticancer pharmaceutical composition comprising cyclophosphosamide, 5-fluorouracil and red ginseng polysaccharide as active ingredients as anticancer agents.

EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.

The anticancer pharmaceutical composition of the present invention can maximize the anticancer activity by showing a synergistic effect of the drug even at a small dose of the anticancer agent by the combined administration of the anticancer agent and the red ginseng acid polysaccharide.

In addition, the present invention can reduce the toxicity and side effects of the anticancer agent by using a small dose of the anticancer agent.

The present invention uses cyclophosphamide (CY) or 5-fluorouracil (5-Fu) as an anticancer agent, but the present invention is not limited thereto.

Cyclophosphamide (CY) of the present invention, as described above, as an alkylating agent inhibits DNA replication and RNA transcription and exhibits anticancer activity, and thus is widely used in acute / chronic leukemia and other solid cancers. 5-fluorouracil (5-Fu) is a pyrimidine derivative that inhibits hexane metabolism and is an anticancer agent mainly used for breast cancer, colon cancer, gastric cancer, and pancreatic cancer.

The cyclophosphamide and 5-fluorouracil may be used commercially available products, for example, cyclophosphamide and 5-fluorouracil are commercially available from Sigma Company (St. Louis, MO, USA). You can purchase and use the product.

In addition, the red ginseng acidic polysaccharide (RGAP) used in the present invention is the red ginseng acidic polysaccharide (RGAP) described in Korean Patent Application No. 2001-33115 filed by the present inventors. It can be prepared according to the method, the sugar composition of the red ginseng acid polysaccharide is 41.5-61.5% glucuronic acid, 3.9-5.9% galacturonic acid, glucose 15.1-35.1% and arabinos 0.5-2.5%, the molecular weight is 12,000- It is in the range of 450,000 Da.

In the present invention, when cyclophosphamide is used as an anticancer pharmaceutical composition, cyclophosphamide and red ginseng acid polysaccharide are generally used in a weight ratio of 1: 5 to 3: 100, preferably 1: 5 to 1:10. It is contained in the weight ratio of.

In this case, when the ratio of cyclophosphamide and red ginseng acid polysaccharide is less than 1: 5 weight ratio, relatively large doses of cyclophosphamide should be used. Not desirable to apply. In addition, when the ratio of cyclophosphamide and red ginseng acid polysaccharide exceeds 3: 100 weight ratio, the dosage of cyclophosphamide is small, so that the synergistic effect of the drug cannot be effectively maximized.

Furthermore, in the 1: 5 to 1:10 weight ratio of cyclophosphamide and red ginseng acid polysaccharide, the antitumor synergistic effect as well as antitumor synergistic effect will be optimally satisfied.

In the present invention, when 5-fluorouracil is used as an anticancer pharmaceutical composition, 5-fluorouracil and red ginseng acid polysaccharide are generally in a weight ratio of 1:10 to 1:40, preferably 1:10 to 1 It is contained in the weight ratio of 20.

In this case, as in the case of the cyclophosphamide, the ratio of 5-fluorouracil and red ginseng acid polysaccharide is less than 1:10 by weight, so a relatively large dose of 5-fluorouracil should be used. It is not preferable to apply to the present invention to reduce the side effects, and when the ratio of 5-fluorouracil and red ginseng acid polysaccharide exceeds 1:40 weight ratio, the dosage of 5-fluorouracil is small to effectively Synergistic effect is not maximized.

The anticancer pharmaceutical composition of the present invention can be used in combination with a physiologically acceptable carrier. Examples of the physiologically acceptable carrier include oral administration carriers, carriers for injection, or carriers for topical administration.

More specific examples of carriers for oral administration include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, or flavoring agents. Examples of carriers for injection include preservatives, analgesics, Solubilizers or stabilizers, and examples of the carrier for topical administration include bases, excipients, lubricants, and preservatives.

Furthermore, the anticancer pharmaceutical composition of the present invention may contain other conventional ingredients known as additives to those skilled in the art of anticancer drugs. The additives include, for example, an antacid to prevent the drug from being degraded by gastric acid upon oral administration.

The pharmaceutical composition for anticancer prepared according to the present invention is a cyclophosphamide, 5 using a small amount of an anticancer agent by synergy by the combination of cyclophosphamide or 5-fluorouracil and red ginseng acid polysaccharide (RGAP), 5 It exhibits synergistic anti-cancer activity that is maximized than the anticancer activity exhibited by the respective doses of fluorouracil or red ginseng acid polysaccharide (RGAP). Furthermore, small doses of anticancer drugs can be used to reduce the toxicity and serious side effects caused by the anticancer drugs.

The anticancer pharmaceutical composition as described above is to treat the cancer by administering to the patient in an effective amount, wherein the dosage forms suitable for administration are solid preparations such as tablets, hard / soft capsules, pills, powders and oral solution, syrup It may be administered orally, or parenterally, such as intravenous, subcutaneous, or intraperitoneal administration, or applied to topical areas by including solutions such as suspensions and injections. In addition, oral administration solid preparations, such as tablets, may be formulated into a formulation coated with enteric skin and administered.

In this case, the proper dosage may be modified by various factors such as the type and severity of cancer, age, and the condition of the patient, and the specific dosage is described below by those skilled in the art of pharmacy and It can be estimated easily based on an experimental example.

On the other hand, the anticancer composition provided by the present invention is effectively applicable to the majority of anticancer agents whose use is limited due to severe toxicity and side effects in addition to the cyclophosphamide or 5-fluorouracil described above.

Hereinafter, the present invention will be described in more detail through Examples and Experimental Examples.

Preparation Example 1 Preparation of Red Ginseng Acid Polysaccharide (RGAP)

Alcohol extracts were prepared from six-year-old red ginseng ( Panax ginseng CA Meyer, Yang Ginseng 30, Korea Ginseng Corporation), and the remaining red ginseng residues were hot-air dried at 60 ° C. for 2 days, and then pulverized. After extraction with hot water (repeat 4 times at 95 ~ 00 ℃ for 3 hours), ultrafiltration (Ultrafiltration Kit, Milipore Co., MA, USA) was used to divide the molecular weight above 10KD and below.

The double molecular weight compound having a molecular weight of 10KD or more was added 5 times (v / v) of 95% ethanol and left for 24 hours at 4 ℃ and hot air dried to prepare a red ginseng acid polysaccharide (RGAP).

<Example 1>

100 mg of red ginseng acid polysaccharide (RGAP) prepared in Preparation Example 1 and 3 mg of cyclophosphamide (CY) were dissolved in physiological saline to prepare an injection solution.

<Example 2>

100 mg of red ginseng acid polysaccharide (RGAP) prepared in Preparation Example 1 and 10 mg of cyclophosphamide (CY) were dissolved in physiological saline to prepare an injection solution.

<Example 3>

100 mg of red ginseng acid polysaccharide (RGAP) and 20 mg of cyclophosphamide (CY) prepared in Preparation Example 1 were dissolved in physiological saline to prepare an injection solution.

<Example 4>

100 mg of red ginseng acid polysaccharide (RGAP) and 2.5 mg of 5-fluorouracil (5-Fu) prepared in Preparation Example 1 were dissolved in physiological saline to prepare an injection solution.

Example 5

100 mg of red ginseng acid polysaccharide (RGAP) prepared in Preparation Example 1 and 5 mg of 5-fluorouracil (5-Fu) were dissolved in physiological saline to prepare an injection solution.

<Example 6>

100 mg of red ginseng acid polysaccharide (RGAP) and 10 mg of 5-fluorouracil (5-Fu) prepared in Preparation Example 1 were dissolved in physiological saline to prepare an injection solution.

<Comparative Example 1 to Comparative Example 3>

The administration of 3 mg / kg, 10 mg / kg and 20 mg / kg of cyclophosphamide (CY), commercially available from Sigma Company (St. Louis, MO, USA), was made as Comparative Examples 1 to 3.

<Comparative Example 4 to Comparative Example 6>

The administration of 2.5 mg / kg, 5.0 mg / kg, and 10 mg / kg, respectively, of 5-fluorouracil (5-Fu) commercially available from Sigma Company (St. Louis, MO, USA) was set as Comparative Examples 4-6.

Comparative Example 7

100 mg of red ginseng acid polysaccharide (RGAP) prepared in Preparation Example 1 was dissolved in physiological saline to prepare an injection solution.

Experimental Example 1 Life-Expansion Effect of Cyclophosphamide (CY) and Red Ginseng Acid Polysaccharide (RGAP) Compositions on Cancer Cells

This study measured the lifespan extension effect of cyclophosphamide (CY) and red ginseng acid polysaccharide (RGAP) composition on cancer cell transplant mice. The life extension effect on cancer cells was determined using a multiple cancer model using sarcoma 180 cells. Measured.

An ICR mouse (20-23 g, 4-5 weeks old), ingested free of solid feed and water, was used at a room humidity of 23 ± ° C and a relative humidity of 40-60%. 100 μl of cell solution (1 × 10 ⁶ cells) diluted in physiological saline with ascites cancer cells (sarcoma-180, sarcoma cancer) was injected into the abdominal cavity, and Example 1, Comparative Example 1, Comparative Example 2 and Comparative Example were used. The drug prepared in 7 was intraperitoneally administered once daily for 7 days, and the average survival days were observed, respectively, and the survival of mice was observed at 30 days. Survival was measured from the survival of mice on day 30, and the results are summarized in the graphs of Table 1 and FIG. 2 together with the average survival days. The survival rate was calculated by the following equation.

As can be seen in Table 1 and Figure 1, in the case of Example 1 according to the present invention by administering the composition of cyclophosphamide and red ginseng acid polysaccharide, 30 days survival rate is 71%, showing a much improved mouse survival rate In Comparative Example 1, Comparative Example 2, and Comparative Example 7, which were administered with cyclophosphamide (3 mg / kg or 10 mg / kg) or red ginseng acid polysaccharide (100 mg / kg) alone, the survival rates at 14 days were 14% and 43%, respectively. Only 43% were measured.

Therefore, the composition of cyclophosphamide and red ginseng acid polysaccharide can maximize the anticancer activity by showing the synergistic effect of the drug even at a low dose of the anticancer drug cyclophosphamide, and administer the anticancer drug by using a small dose of the anticancer agent cyclophosphamide. Toxic effects and side effects can be reduced.

Experimental Example 2 Antitumor Effects of Cyclophosphamide (CY) and Red Ginseng Acid Polysaccharide (RGAP) Compositions on Cancer Cells

This study measured the antitumor effect of cyclophosphamide (CY) and red ginseng acid polysaccharide (RGAP) composition on cancer cells. The antitumor effect on cancer cells was measured using a solid cancer model using LL2 lung carcinoma cancer cells. .

C57BL / 6 mice (20.0 ± 0.2g, 5-6 weeks of age), which were freely fed solid feed and water at conditions of 23 ± 3 ° C and 40-60% relative humidity, were used. Seven mice per group were used. use, the dorsal tumor cells by subcutaneous injection of HBSS (Hank's balanced salt solution without sodium bicarbonate and phenol red), a cancer cell (LL2 lung carcinoma, concentration of 1x10 ⁶ cells) cell solution (1x10 ⁶ cells) of 200㎕ suspended in the After 24 hours of incubation, the medicines of Examples 2, 3, Comparative Example 2, Comparative Example 3 and Comparative Example 7 were intraperitoneally administered once daily for 7 days, and 20 days later, the solid cancer was extracted and extracted. The weight was measured. The inhibition rate of solid rock formation was calculated from the weight of the extracted solid rock, and the results are summarized as a graph in Table 2 and FIG. 2.

As can be seen in Table 2 and Figure 2, in the case of Example 2 according to the present invention, despite using the same cyclophosphamide content and the same red ginseng acid polysaccharide content of Comparative Example 7 The weight of 287 ± 132mg was confirmed that the inhibition of solid cancer production compared to the control group was up to 38.8%.

In the case of Example 3, despite using the same cyclophosphamide content and the same red ginseng acid polysaccharide content as Comparative Example 7, the weight of solid cancer was 128 ± 81 mg, which reduced the inhibition rate of solid cancer production to 72.7% compared to the control group. As a result, a much improved rate of inhibition of solid cancer production was found.

However, in the control group, the solid cancer weight was 469 ± 134 mg, and in Comparative Examples 2 and 3, in which cyclophosphamide was administered at 10 mg / kg and 20 mg / kg, respectively, 324 ± 71 mg and 167 ± 183 mg, respectively, and solid cancer production inhibition rate was 31.0. % And 64.4%. In addition, in the case of Comparative Example 7 administered with red ginseng acid polysaccharide 100mg / kg alone, the solid cancer weight was 339 ± 163mg, and the inhibition rate of solid cancer production was only 27.7% compared to the control group.

Therefore, the present invention can maximize the anticancer activity by showing a synergistic effect of the drug even at a small dose of cyclophosphamide, and by using a small dose of cyclophosphamide can reduce the toxicity and side effects of the anticancer drug administration.

Experimental Example 3 Life-Expansion Effect of 5-Fluorouracil (5-Fu) and Red Ginseng Acid Polysaccharide (RGAP) Compositions on Cancer Cells

IRC mice (20-23 g, 4-5 weeks old) were prepared as experimental animals as in Experimental Example 1, and 7 mice were used per group, and cancer cells (sarcoma-180, sarcoma cancer) were placed in the abdominal cavity. Cancer cells were cultured by injecting 100 μl of a cell solution (1 × 10 ⁶ cells) diluted in physiological saline, and intraperitoneally administered the drugs of Example 4, Comparative Example 4 and Comparative Example 7 once daily for 7 days and averaged survival after 24 hours. The number of days was observed and the survival of mice was observed at 30 days. Survival rate was calculated from the survival of mice on day 30 as in Experimental Example 1, and the results are summarized as a graph in Table 3 and FIG. 3 together with the average survival days.

As can be seen in Table 3 and FIG. 3, in Example 4 according to the present invention, the survival rate of the mouse was 62.5% at the same 5-fluorouracil dose as in Comparative Example 4 and the same red ginseng acid polysaccharide dose as in Comparative Example 7. As it can be confirmed that much improved, thus, it was confirmed that the synergistic effect of anticancer survival 1.7 times higher compared to the survival rate (37.5%) of Comparative Example 4 administered 5-fluorouracil alone by 2.5mg / kg.

However, in Comparative Example 4 and Comparative Example 7 administered with 5-fluorouracil (2.5 mg / kg) or red ginseng acid polysaccharide (100 mg / kg) alone, the survival rates were 37.5% and 25.0% at 30 days, respectively.

From these results, the present invention can maximize the anticancer activity by showing a synergistic effect of the drug even at a small dose of the anticancer agent 5-fluorouracil, and by using a small dose of the anticancer agent 5-fluorouracil, It can reduce side effects.

Experimental Example 4 Antitumor Effects of 5-Fluorouracil (5-Fu) and Red Ginseng Acid Polysaccharide (RGAP) Compositions on Cancer Cells

C57BL / 6 mice (20.0 ± 0.2 g, 5-6 weeks old) prepared as in Experimental Example 2 were used in each group of 7 mice, and suspended in HBSS (Hank's balanced salt solution without sodium bicarbonate and phenol red) on their backs. Cancer cells were cultured by subcutaneous injection of 200 μl of a cell solution (1 × 10 ⁶ cells) of solid cancer cells (LL2 lung carcinoma, concentration 1 × ^{10 6} cells), followed by Example 5, Example 6 and Comparative Examples 5-7. The drug was intraperitoneally administered once daily for 7 days and the solid cancer produced after 20 days was extracted and its weight was measured. The inhibition rate of solid rock formation was calculated from the weight of the extracted solid rock, and the results are summarized as a graph in Table 4 and FIG. 4.

As can be seen in Table 4 and Figure 4, in the case of Example 5 according to the present invention, despite the same 5-fluorouracil content and the same red ginseng acidic polysaccharide content of Comparative Example 7 was administered solid cancer The weight of 528 ± 38mg reduced solid cancer production inhibition rate by 40.9%.

In the case of Example 6, the weight of solid cancer was 234 ± 198 mg in the experiment administered with the same 5-fluorouracil content and the same red ginseng acid polysaccharide content as Comparative Example 6, and the inhibition rate of solid cancer production was 73.8% compared to the control group. As a result of the reduction, it was confirmed that the inhibition rate was much improved.

However, in the control group, the solid cancer weight was 894 ± 439mg, and in Comparative Example 5 and Comparative Example 6, the solid cancer weights were 666 ± 329mg and 451 ± 219mg, respectively, and solid tumor formation inhibition rates were 25.5% and 49.6%, respectively. In Eosin, the weight of solid cancer was 875 ± 447 mg, which was only 2.1% of solid cancer production inhibition.

Therefore, the present invention can maximize the anticancer activity by showing a synergistic effect of the drug even at a small dose of the anticancer agent 5-fluorouracil, and by using a small dose of the anticancer agent 5-fluorouracil, the toxicity and side effects of the anticancer drug administration Can be reduced.

Preparation Example 2 Tablet Preparation

       100 mg of red ginseng acid polysaccharide prepared in Preparation Example 1 and 3 mg of cyclophosphamide were uniformly mixed, and then 20 mg of microcrystalline cellulose and 10 mg of sodium starch glycolate were added and compression molded in a tablet press to prepare a tablet.

Preparation Example 3 Preparation of Injection

10 mg of red ginseng acid polysaccharide prepared in Preparation Example 1 and 1 mg of cyclophosphamide were dissolved in distilled water for injection, followed by addition of 2 mg of sodium phosphate and 5 mg of dimethyl sulfoxide, followed by sterilization.

Preparation Example 4 Capsule Preparation

100 mg of red ginseng acid polysaccharide prepared in Preparation Example 1 and 5 mg of 5-fluorouracil were uniformly mixed, and then 3 mg of magnesium stearate and 20 mg of talc were added and charged in a charger to prepare a capsule.

As described above, when the anticancer composition according to the present invention is used as an anticancer agent or an anticancer adjuvant, the present invention exhibits a synergistic effect of the drug even at a small dose of the existing anticancer agent by combining the anticancer agent and the red ginseng acid polysaccharide, thereby maximizing the anticancer activity. Toxicity and side effects of anticancer drugs can be reduced by using a small dose of the existing anticancer drugs.

Figure 1 shows the results of measuring the average survival days and the survival rate of the mouse 30 days when the mice cultured cancer cells (sarcoma-180) according to Experimental Example 1 cyclophosphamide, red ginseng acid polysaccharide, and combinations thereof Graph,

Figure 2 is calculated from the weight of the solid cancer produced 20 days after the administration of cyclophosphamide, red ginseng polysaccharide, and combinations thereof to mice cultured with cancer cells (LL / 2 lung carcinoma) by Experimental Example 2 Graph for the rate of inhibition of solid rock formation,

Figure 3 is the result of measuring the average survival days and the survival rate of the mice 30 days when 5-fluorouracil, red ginseng acid polysaccharide, and combinations thereof were administered to the mice cultured cancer cells (sarcoma-180) by Experimental Example 3 A graph showing, and

Figure 4 is calculated from the weight of solid cancer produced after 20 days when 5-fluorouracil, red ginseng polysaccharide, and combinations thereof were administered to mice incubated with cancer cells (LL / 2 lung carcinoma) by Experimental Example 4, respectively. It is a graph comparing the inhibition rate of solid rock formation.

Claims (12)

Anticancer and anticancer pharmaceutical composition comprising an anticancer agent and red ginseng acid polysaccharide (RGAP) as an active ingredient According to claim 1, wherein the anticancer agent is anti-cancer and anticancer pharmaceutical composition, characterized in that cyclophosphamide (cyclophosphamide) According to claim 1, wherein the anticancer agent is 5-fluorouracil (5-fluorouracil) characterized in that the anticancer and anticancer pharmaceutical composition According to claim 1, wherein the red ginseng acid polysaccharide has a sugar composition of glucuronic acid (glucuronic acid) 41.5 ~ 61.5%, galacturonic acid (galacturonic acid) 3.9 ~ 5.9%, glucose 15.1 ~ 35.1% and arabinose (arabinose) 0.5 to 2.5%, the molecular weight of the anticancer and anticancer pharmaceutical composition, characterized in that in the range of 12,000 ~ 450,000 Da The pharmaceutical composition for anticancer and anticancer activity according to claim 2 or 4, wherein the cyclophosphamide and the red ginseng acid polysaccharide are contained at a weight ratio of 1: 5 to 3: 100. According to claim 5, Anti-cancer and anticancer pharmaceutical composition comprising the cyclophosphamide and red ginseng acid polysaccharide in a weight ratio of 1: 5 ~ 1:10. The anticancer and anticancer pharmaceutical composition according to claim 3 or 4, wherein the 5-fluorouracil and the red ginseng acid polysaccharide are contained at a weight ratio of 1:10 to 1:40. 8. The anticancer and anticancer pharmaceutical composition according to claim 7, wherein the 5-fluorouracil and the red ginseng acid polysaccharide are contained in a weight ratio of 1:10 to 1:20.         Anticancer and anti-cancer pharmaceutical formulations characterized in that the red ginseng acid polysaccharide (RGAP) composition is formulated in unit dosage form with a pharmaceutically acceptable carrier.        10. The anticancer and anticancer pharmaceutical formulation according to claim 9, wherein the unit dosage form is selected from tablets, hard or soft capsules, granules, liquids, suspensions, injectable solutions or suspensions.        The pharmaceutical formulation for anticancer and anticancer activity according to claim 9 or 10, wherein the anticancer agent is cyclophosphamide.        11. The anticancer and anticancer pharmaceutical formulation of claim 9, wherein the anticancer agent is 5-fluorouracil.